$474 Million is the total value of Virtus ETF Advisers LLC's 434 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| WDAY | Exit | WORKDAY INCcl a | $0 | – | -80 | -100.0% | -0.03% | – |
| AAP | Exit | ADVANCE AUTO PARTS INC | $0 | – | -92 | -100.0% | -0.03% | – |
| EWBC | Exit | EAST WEST BANCORP INC | $0 | – | -339 | -100.0% | -0.03% | – |
| IVZ | Exit | INVESCO LTD | $0 | – | -952 | -100.0% | -0.04% | – |
| ISRG | Exit | INTUITIVE SURGICAL INC | $0 | – | -32 | -100.0% | -0.04% | – |
| APTX | Exit | APTINYX INC | $0 | – | -12,427 | -100.0% | -0.11% | – |
| FB | Exit | FACEBOOK INCcl a | $0 | – | -435 | -100.0% | -0.16% | – |
| CRNX | Exit | CRINETICS PHARMACEUTICALS IN | $0 | – | -7,934 | -100.0% | -0.38% | – |
| INO | Exit | INOVIO PHARMACEUTICALS INC | $0 | – | -52,943 | -100.0% | -0.42% | – |
| STIM | Exit | NEURONETICS INC | $0 | – | -13,535 | -100.0% | -0.44% | – |
| KNSA | Exit | KINIKSA PHARMACEUTICALS LTD | $0 | – | -11,763 | -100.0% | -0.45% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $0 | – | -50,655 | -100.0% | -0.46% | – |
| MRKR | Exit | MARKER THERAPEUTICS INC | $0 | – | -39,672 | -100.0% | -0.56% | – |
| KDMN | Exit | KADMON HLDGS INC | $0 | – | -119,987 | -100.0% | -0.67% | – |
| ASRT | Exit | ASSERTIO THERAPEUTICS INC | $0 | – | -64,315 | -100.0% | -0.69% | – |
| OPTN | Exit | OPTINOSE INC | $0 | – | -34,499 | -100.0% | -0.76% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -27,492 | -100.0% | -0.78% | – |
| NITE | Exit | NIGHTSTAR THERAPEUTICS PLCadr | $0 | – | -23,777 | -100.0% | -1.28% | – |
| ACOR | Exit | ACORDA THERAPEUTICS INC | $0 | – | -48,468 | -100.0% | -1.37% | – |
| ONCE | Exit | SPARK THERAPEUTICS INC | $0 | – | -19,751 | -100.0% | -4.78% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| REGENERON PHARMACEUTICALS | 31 | Q3 2023 | 1.8% |
| INCYTE CORP | 31 | Q3 2023 | 2.1% |
| ENANTA PHARMACEUTICALS INC | 31 | Q3 2023 | 2.2% |
| EXELIXIS INC | 31 | Q3 2023 | 1.8% |
| VANDA PHARMACEUTICALS INC | 31 | Q3 2023 | 1.7% |
| IRONWOOD PHARMACEUTICALS INC | 31 | Q3 2023 | 2.0% |
| LIGAND PHARMACEUTICALS INC | 31 | Q3 2023 | 1.5% |
| GILEAD SCIENCES INC | 31 | Q3 2023 | 1.6% |
| HALOZYME THERAPEUTICS INC | 31 | Q3 2023 | 1.7% |
View Virtus ETF Advisers LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-15 |
| 13F-HR | 2023-11-07 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Virtus ETF Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.